Magnolia Medical Technologies, Inc. v. Kurin, Inc.
Patent Trial and Appeal Board
Holding
When a petitioner previously contested validity of the challenged patent in completed district-court litigation on the same or similar § 102/§ 103 grounds that could have been presented to the Office, had a full and fair opportunity to litigate them, and lost due to a petitioner-controlled litigation failure, the Board may discretionarily deny institution as an improper repeat challenge or “second bite at the apple.” This is not an NHK-Fintiv factor analysis; it is a public-interest discretionary-denial rule grounded in the AIA’s purpose of providing a litigation alternative, not an additional forum after a litigation loss.
Why It Matters
No prior precedent directly addressed this issue; Magnolia clarifies that discretionary denial can rest on a completed district-court validity contest even where the jury did not reach the petitioner’s § 102/§ 103 theories because the petitioner’s expert was precluded. For petitioners, institution is less likely if the petition follows a district-court loss and recycles invalidity theories that were or could have been litigated; the petition must avoid looking like a post-loss cure for litigation mistakes and must explain why the Board is being used as an alternative, not a second forum. For patent owners, this enables a discretionary-denial record focused on prior litigation of the same or similar grounds, substantial party investment, a completed trial or adverse validity outcome, and petitioner-controlled procedural defaults such as expert exclusion. The Director relied on Apple Inc. v. Squires and United States v. Arthrex for broad, unreviewable institution discretion, and on Saint Regis Mohawk Tribe v. Mylan for the public-interest/regulatory character of AIA review.
Full Summary
Key Points
- LEGAL TEST OR STANDARD: No numbered or lettered multi-factor test was applied; the Director considered the “totality of the evidence and arguments presented” and asked whether the Petition was “outside the purpose of AIA reviews” because Petitioner was “not attempting to use the Board as an alternative to the litigation” but instead seeking “a repeat challenge or second bite at the apple.”
- TRIGGERING FACTS: The challenged patent had already been tried in district court, where a jury found the patent not invalid; the petitioner’s anticipation and obviousness theories were similar to those in the IPR but were not presented to the jury because the district court precluded the petitioner’s invalidity expert on November 3, 2025 for failing to disclose the claim construction underlying those opinions; the petitioner filed the IPR only after that preclusion order; and the Director found the same grounds could have been presented to the Office and that the petitioner had a full and fair opportunity to litigate them in court.
- KEY QUOTE: 'The lack of a jury verdict as to anticipation or obviousness in the now-completed jury trial does not entitle Petitioner to re-litigate the same issues at the Office.' (Paper 17, p. 10).
- PRIOR PRECEDENT AFFECTED: No prior precedential or informative decision is directly affected.
- PRACTICE TIP: Patent owners should use the POPR or discretionary-denial briefing to show that the petitioner already chose district court for the same or similar invalidity theories, lost or suffered a petitioner-controlled litigation default, and is now seeking a second bite rather than a true litigation alternative.
- PTAB Director Review · Oct. 8, 2026Notice of Decisions on Institution — 2026-10-08
- PTAB Director Review · Sept. 24, 2026Biocon Biologics Limited et al. v. Regeneron Pharmaceuticals, Inc.
- PTAB Director Review · Sept. 23, 2026Notice of Decisions on Institution — 2026-09-23
- PTAB Director Review · Sept. 23, 2026Nearmap US, Inc. v. Eagle View Technologies, Inc.
- PTAB Director Review · Aug. 25, 2026Aesthetic Management Partners, LLC and Aesthetic Management Partners, Inc. v. HydraFacial LLC